Showing results (1-10 of 79) with videos related to
Sort By:
Pageof 8
Health Policy (Amsterdam, Netherlands)|February 28, 2012
Stakeholders involvement by HTA Organisations: why is so different?Marianna Cavazza, Claudio JommiPlos One|September 8, 2018
Health care costs of influenza-related episodes in high income countries: A systematic reviewCarlo Federici, Marianna Cavazza, Francesco Costa, et al.BMC Health Services Research|December 5, 2021
The economic impact of compassionate use of medicinesClaudio Jommi, Federico Pantellini, Lisa Stagi, et al.Nutrition (Burbank, Los Angeles County, Calif.)|September 21, 2019
Patient access to oral nutritional supplements: Which policies count?Marianna Cavazza, Helen Banks, Maurizio Muscaritoli, et al.BMC Health Services Research|January 23, 2024
Cost of implementing CAR-T activity and managing CAR-T patients: an exploratory studyMaria Caterina Cavallo, Marianna Cavazza, Francesca Bonifazi, et al.Medicina (Kaunas, Lithuania)|June 27, 2025
Obesity in Italy: An Empirical Analysis of Healthcare Consumption, Quality of Life and ComorbiditiesElenka Brenna, Claudio JommiDrug Design, Development and Therapy|November 25, 2014
The role of health technology assessment bodies in shaping drug developmentOriana Ciani, Claudio JommiPharmacoeconomics - Open|February 10, 2023
The Evaluation of Drug Innovativeness in Italy: Key Determinants and Internal ConsistencyClaudio Jommi, Carlotta GaleoneHealth Policy (Amsterdam, Netherlands)|July 11, 2006
Public administration and R&D localisation by pharmaceutical and biotech companies: a theoretical framework and the Italian case-studyClaudio Jommi, Silvia ParuzzoloPharmacoeconomics|December 20, 2007
The last decade of Italian pharmaceutical policy: instability or consolidation?Giovanni Fattore, Claudio JommiPageof 8